ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio
1. Evogene will sell Lavie Bio Ltd. to ICL. 2. ICL will acquire Evogene's MicroBoost AI for AG. 3. The transaction is expected to close in Q2 2025.
FAQ
Why Bullish?
The acquisition by ICL can provide Evogene with capital and renewed focus. Historical precedent shows that strategic divestitures often boost remaining company valuation.
How important is it?
The strategic acquisition could impact Evogene's focus and resource allocation significantly. The potential for enhanced investment and market confidence will likely influence stock performance.
Why Long Term?
The structural changes from the acquisition may enhance operational efficiency and profitability over time. Similar transactions have historically led to long-term value creation.
Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products
REHOVOT, Israel, April 21, 2025 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a definitive agreement under which ICL will acquire the majority of activity of Evogene's subsidiary, Lavie Bio Ltd. As part of the agreement, ICL will also acquire Evogene's MicroBoost AI for AG platform.
The transaction is expected to close during the second quarter of 2025, subject to the fulfillment of customary closing conditions.